Actively Recruiting
Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
Led by University of Cologne · Updated on 2024-07-26
120
Participants Needed
1
Research Sites
205 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of the trial is to establish an individualized first-line treatment incorporating checkpoint inhibition for early-stage unfavorable cHL, which is effective and well tolerated.
CONDITIONS
Official Title
Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 60 years for the main trial cohort
- Age 61 years or older and eligible for AVD chemotherapy based on CIRS-G score and investigator assessment for the exploratory cohort
- First diagnosis of treatment-naive classical Hodgkin lymphoma
- Early-stage unfavorable disease defined as stage IA, IB, and IIA with any of the following risk factors: large mediastinal mass, extranodal lesions, elevated erythrocyte sedimentation rate, or involvement of 3 or more nodal areas
- Stage IIB with risk factors of elevated erythrocyte sedimentation rate or involvement of 3 or more nodal areas
You will not qualify if you...
- Presence of nodular-lymphocyte predominant Hodgkin lymphoma
- Presence of grey-zone lymphoma
- Involvement of lymphoma in the central nervous system
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
1st Department of Medicine, Cologne University Hospital
Cologne, Germany
Actively Recruiting
Research Team
M
Michael Fuchs
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here